Direxion Daily S&P Biotech Bear 3X ETF (LABD)
5 Inverse ETFs That Gained More Than 20% in April
The U.S. stock market wrapped up April with losses, snapping a five-month winning streak and marking the market's worst month of 2024. This has resulted in huge gains for inverse or inverse-leveraged ETFs.
Top Performing Leveraged/Inverse ETFs: 04/21/2024
These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
Best Inverse/Leveraged ETFs of Last Week
Wall Street delivered a downbeat performance last week.
LABD: An Absolute Avoid
Shorting and inverse bets don't work over time on average, making inverse funds like Direxion Daily S&P Biotech Bear 3X Shares ETF a big avoid. The LABD ETF is a triple-leveraged inverse ETF that focuses on the biotechnology sector and aims to profit from a decline in the value of the index it tracks. LABD is not suitable for long-term investment, incurs high costs, and experiences high volatility, making it a high-risk, high-reward investment.
Top Performing Leveraged/Inverse ETFs: 09/10/2023
Top Performing Levered/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
LABD: 3X Leveraged Inverse Fund In Biotechnology Sector Is Best Avoided
Direxion Daily S&P Biotech Bear 3X Shares ETF failed to generate decent yield & price growth over the past 90 months. I don't foresee this fund generating positive growth in the near future, either. LABD has a high expense ratio, and its investments in derivatives enhance the chances of default. Its drift is also at its worst since the fund's inception. LABD is a short-term trading tool for seasoned traders who have a strategy with clear entry and exit signals, and have a strong understanding of leverage.
5 Least-Hurt Biotech ETFs of the Last Week
Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.
The Sell Rating Of LABD Is Reaffirmed
Since July 8 when I rated LABD a SELL, the underlying biotechnology index has moved very little up or down; LABD declined 25.22%. The biotechnology sector has done relatively well during the last four months; it is expected to continue trading sideways.
LABD: A Bad Bad Drift
Leveraged ETFs have a non-linear, unpredictable behavior. A drift dashboard with 22 of them.
LABD: 3X Leveraged Investments Not Suitable For Long Term
3X inverse derivative investments are extremely volatile and risky.
Take a Look at Inverse ETFs Up More Than 50% YTD
Here we highlight some Inverse ETFs up more than 50% so far in 2022.
5 Best Inverse-Leveraged ETFs of Last Week
Last week was downbeat for Wall Street? Apart from the Omicron woes, inflationary pressure continued to bother markets.
This Bearish Biotech ETF Is up 16% in the Past Month
The biotech sector was one of the darlings amid the vaccine rally in 2020, but there's since been some bearishness, which is benefiting the Direxion Daily S&P Biotech Bear 3X Shares (LABD). LABD climbed 16% the past month, giving bearish biotech traders something to cheer about.
5 Inverse ETFs Jump Most on Market Sell-Off
We have highlighted the five best-leveraged inverse ETFs that piled up handsome gains on the broad sell-off.
September Lull Starts: Inverse ETFs Won Last Week
Wall Street witnessed a bloodbath last week, resulting in a solid run-up in inverse ETFs.
Top Inverse/Leveraged ETFs of Last Week
Last week was mixed for Wall Street. Tax hike fears, rising COVID-19 cases and still-existing rising rate worries led to the volatility.
We Skipped The 3x Fangdango
Price movement is best explained by finite state theory as opposed to continuous time. These strategies are best suited for 401(k) accounts where there are no tax or record keeping issues.